Antibody and T-cell responses specific for the androgen receptor in patients with prostate cancer

Prostate

Volumn 67, Issue 16, 2007, Pages 1729-1739

  Olson, Brian M ^a,b   McNeel, Douglas G ^b,c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c University of Wisconsin Health   (United States)

Author keywords

Antigen; Auto antibodies; Cellular immunity; Pre existing immunity

Indexed keywords

ANDROGEN RECEPTOR; AUTOANTIBODY; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2; INTERLEUKIN 10;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CANCER STAGING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTATE CANCER; SERUM; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, NEOPLASM; ANTIBODY SPECIFICITY; AUTOANTIBODIES; BLOTTING, WESTERN; CELL GROWTH PROCESSES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; INTERFERON TYPE II; INTERLEUKIN-10; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; T-LYMPHOCYTES;

EID: 36849061224     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20652     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics. CA Cancer J Clin 2006;56(2):106-130.
2. Carter HB, Coffey DS. The prostate: An increasing medical problem. Prostate 1990;16(1):39-48.
3. Swanton C, Futreal A, Eisen T. Her2-targeted therapies in non-small cell lung cancer. Clin Cancer Res 2006;12(14 Pt 2):4377s-4383s.
4. Baxevanis CN, Sotiriadou NN, Gritzapis AD, Sotiropoulou PA, Perez SA, Cacoullos NT, Papamichail M. Immunogenic HER-2/ neu peptides as tumor vaccines. Cancer Immunol Immunother 2006;55(1):85-95.
5. Marshall J. Carcinoembryonic antigen-based vaccines. Semin Oncol 2003;30 (3 Suppl 8):30-36.
6. Disis ML, Grabstein KH, Sleath PR, Cheever MA. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 1999;5(6):1289-1297.
7. Acres B, Limacher JM. MUC1 as a target antigen for cancer immunotherapy. Expert Rev Vaccines 2005;4(4):493-502.
8. Pavlenko M, Roos AK, Lundqvist A, Palmborg A, Miller AM, Ozenci V, Bergman B, Egevad L, Hellstrom M, Kiessling R, Masucci G, Wersall P, Nilsson S, Pisa P. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 2004;91(4):688-694.
9. Kaufman HL, Wang W, Manola J, DiPaola RS, Ko YJ, Sweeney C, Whiteside TL, Schlom J, Wilding G, Weiner LM. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): A trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2004;22(11):2122-2132.
10. Johnson LE, Frye TP, Arnot AR, Marquette C, Couture LA, Gendron-Fitzpatrick A, McNeel DG. Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP). Vaccine 2006;24(3):293-303.
11. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24(19): 3089-3094.
12. Mincheff M, Tchakarov S, Zoubak S, Loukinov D, Botev C, Altankova I, Georgiev G, Petrov S, Meryman HT. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: A phase I/II clinical trial. Eur Urol 2000;38(2):208-217.
13. Morris MJ, Divgi CR, Pandit-Taskar N, Batraki M, Warren N, Nacca A, Smith-Jones P, Schwartz L, Kelly WK, Slovin S, Solit D, Halpern J, Delacruz A, Curley T, Finn R, O'Donoghue JA, Livingston P, Larson S, Scher HI. Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. Clin Cancer Res 2005;11(20):7454-7461.
14. Salgaller ML, Lodge PA, McLean JG, Tjoa BA, Loftus DJ, Ragde H, Kenny GM, Rogers M, Boynton AL, Murphy GP. Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA). Prostate 1998;35(2):144-151.
15. Ranieri E, Kierstead LS, Zarour H, Kirkwood JM, Lotze MT, Whiteside T, Storkus WJ. Dendritic cell/peptide cancer vaccines: Clinical responsiveness and epitope spreading. Immunol Invest 2000;29(2):121-125.
16. Jager E, Ringhoffer M, Karbach J, Arand M, Oesch F, Knuth A. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: Evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 1996;66(4):470-476.
17. Wojtowicz-Praga S, Verma UN, Wakefield L, Esteban JM, Hartmann D, Mazumder A. Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor beta antibody and interleukin-2. J Immunother Emphasis Tumor Immunol 1996;19(3):169-175.
18. Jager E, Ringhoffer M, Altmannsberger M, Arand M, Karbach J, Jager D, Oesch F, Knuth A. Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 1997;71(2):142-147.
19. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25(2):276-308.
20. Yang Q, Fung KM, Day WV, Kropp BP, Lin HK. Androgen receptor signaling is required for androgen-sensitive human prostate cancer cell proliferation and survival. Cancer Cell Int 2005;5(1):8.
21. Sharifi N, Farrar WL. Androgen receptor as a therapeutic target for androgen independent prostate cancer. Am J Ther 2006;13(2): 166-170.
22. Edwards J, Krishna NS, Grigor KM, Bartlett JM. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003;89(3):552-556.
23. Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 2001;93(22):1687-1697.
24. Boguski MS, Lowe TM, Tolstoshev CM. dbEST-database for "expressed sequence tags". Nat Genet 1993;4(4):332-333.
25. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 1990;5(7):953-962.
26. Thompson J, Zimmermann W. The carcinoembryonic antigen gene family: Structure, expression and evolution. Tumour Biol 1988;9(2-3):63-83.
27. Ruizeveld de Winter JA, Trapman J, Vermey M, Mulder E, Zegers ND, van der Kwast TH. Androgen receptor expression in human tissues: An immunohistochemical study. J Histochem Cytochem 1991;39(7):927-936.
28. McNeel DG, Nguyen LD, Storer BE, Vessella R, Lange PH, Disis ML. Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer. J Urol 2000;164(5):1825-1829.
29. McNeel DG, Nguyen LD, Ellis WJ, Higano CS, Lange PH, Disis ML. Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer. Prostate 2001;47(3):222-229.
30. Dunphy EJ, Eickhoff JC, Muller CH, Berger RE, McNeel DG. Identification of antigen-specific IgG in sera from patients with chronic prostatitis. J Clin Immunol 2004;24(5):492-502.
31. Stevens TL, Bossie A, Sanders VM, Fernandez-Botran R, Coffman RL, Mosmann TR, Vitetta ES. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 1988;334(6179):255-258.
32. Fossa A, Berner A, Fossa SD, Hernes E, Gaudernack G, Smeland EB. NY-ESO-1 protein expression and humoral immune responses in prostate cancer. Prostate 2004;59(4):440-447.
33. Hoeppner LH, Dubovsky JA, Dunphy EJ, McNeel DG. Humoral immune responses to testis antigens in sera from patients with prostate cancer. Cancer Immun 2006;6:1.
34. Sreekumar A, Laxman B, Rhodes DR, Bhagavathula S, Harwood J, Giacherio D, Ghosh D, Sanda MG, Rubin MA, Chinnaiyan AM. Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. J Natl Cancer Inst 2004;96(11): 834-843.
35. Ponniah S, Arah I, Alexander RB. PSA is a candidate self-antigen in autoimmune chronic prostatitis/chronic pelvic pain syndrome. Prostate 2000;44(1):49-54.
36. Liao S, Witte D. Autoimmune anti-androgen-receptor antibodies in human serum. Proc Natl Acad Sci USA 1985;82(24):8345-8348.